feinstein, northwell
Northwell Health's Feinstein Institutes for Medical Research is beginning three studies alongside Sanofi, Gilead Sciences and Regeneron Pharmaceuticals. These studies will test possible treatments for moderate and severe cases of COVID-19. (Photo via Northwell Health)

Northwell Health’s Feinstein Institutes Teams Up with Sanofi, Regeneron Pharmaceuticals, Gilead Sciences to Test COVID-19 Treatments

The research arm of Northwell Health (No. 2 on DiversityInc’s 2019 Top Hospitals & Health Systems), the Feinstein Institutes for Medical Research, is partnering with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi (No. 31 on DiversityInc’s 2019 Top 50 Companies for Diversity) to identify treatments for people hospitalized with moderate to severe cases of the novel coronavirus (COVID-19).

The Feinstein Institutes announced last week the enrollment of three clinical trials aimed at finding an effective treatment for those diagnosed with the coronavirus. Due to the urgency of the issue, there has been a nationwide push for expedited Food and Drug Administration (FDA) approvals of experimental COVID-19 therapies. However, Northwell Health and the Feinstein Institutes announced the trials would continue through the typical, lengthier process to ensure accuracy.

Two of the trials, which will be conducted with Gilead, will involve the drug remdesivir. Remdesivir is an antiviral drug that is designed to reduce the length and intensity of a COVID-19 infection. Northwell Health said the drug had shown promise in working against similar viruses like MERS and SARS in test tubes and animal models. The first trial has room for 400 subjects with severe cases of COVID-19 worldwide. Researchers will administer the drug intravenously in two different durations and measure patients’ bodies’ responses. Feinstein Institutes’ Marcia Epstein, MD, an infectious disease expert, will lead this study.

The other Gilead remdesivir trial will assess two different durations of treatment with the drug and compare it to the current treatment methods in up to 600 patients with moderate cases of COVID-19. Researchers will also look at improvement of symptoms and time of discharge. Prashant Malhotra, MD, will lead this study. Malhotra is an assistant professor of the Institute of Health Innovations & Outcomes Research at Feinstein Institutes and is an infectious disease expert.

In the third study, Feinstein will collaborate with Regeneron and Sanofi. The trial will look at approximately 400 severe or critical cases of COVID-19 in hospitals across the U.S. This trial will study the efficacy of a human antibody called sarilumab that may help prevent complications connected to severe pneumonia in COVID-19 patients. This study adds to a preliminary Chinese trial that found the use of the antibody helped reduce fever in all patients.

China has approved its use to treat patients with severe or critical cases. Negin Hajizadeh, MD, an assistant professor in the Institute of Health Innovations & Outcomes Research and a pulmonary critical care doctor will be leading this study.

To read more about these studies and Northwell’s plans to combat COVID-19, visit northwell.edu.

Latest News

KPMG: Driving Inclusive Virtual Collaboration

Originally published on info.KPMG.us by Michele Meyer-Shipp As social distancing and virtual work have become our new normal, here are five suggestions to help ensure everyone on your team feels included and valued: Communicate often and in different ways. One of the challenges of working remotely is feeling isolated, especially if you’re…

Marriott International Celebrates 93 Years

Originally published on LinkedIn by Bill Marriott, Executive Chairman of the Board at Marriott International. I woke up like a child on Christmas this morning because today marks the 93rd anniversary of Marriott International. When I think back to how my newlywed parents, J.W. and Alice Marriott, started a small root…

Dow Collaborates with Multiple Partners to Develop and Donate Level 2 Medical Isolation Gowns

Originally posted on Dow.com Collaboration included Magna International, Inc., 3M, Cadillac Products Packaging Company, DuPont, Fitesa, Landaal Packaging Systems, Plastixx FFS Technologies, Shurtape and Volkswagen 100,000 isolation gowns to be donated to healthcare professionals For healthcare professionals battling the COVID-19 pandemic, isolation gowns are among the most used and needed…

Hershey Stockholders Elect Victor L. Crawford To Company Board

Originally published on thehersheycompany.com. HERSHEY, Pa., May 18, 2020 (GLOBE NEWSWIRE) — The Hershey Company (NYSE: HSY) today announced the election of Victor L. Crawford to its board of directors. Crawford is the newest Hershey board member and was elected at the company’s recent Annual Stockholder’s Meeting. Victor L. Crawford Crawford brings deep executive and leadership experience to…

Novartis Discusses Navigating Cancer During COVID-19

Originally published on LinkedIn. Watch the recent discussion between Susanne Schaffert, PhD and President of Novartis Oncology and Pat Garcia-Gonzalez, Founder and CEO of The Max Foundation, a patient advocacy group, to learn how they are helping people living with CML stay safe and get the support and treatment they need.